Pharma Industry News

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

The results show that the Lynparza combination therapy significantly improved radiographic progression-free survival

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]